Your browser is no longer supported. Please, upgrade your browser.
EVLO Evelo Biosciences, Inc. daily Stock Chart
Evelo Biosciences, Inc.
Index- P/E- EPS (ttm)-2.73 Insider Own0.13% Shs Outstand32.64M Perf Week11.55%
Market Cap193.80M Forward P/E- EPS next Y-2.21 Insider Trans- Shs Float23.01M Perf Month-3.41%
Income-87.90M PEG- EPS next Q-0.49 Inst Own70.00% Short Float5.27% Perf Quarter-16.34%
Sales- P/S- EPS this Y-39.70% Inst Trans16.96% Short Ratio8.45 Perf Half Y-11.46%
Book/sh2.12 P/B2.00 EPS next Y0.90% ROA-88.10% Target Price- Perf Year-27.60%
Cash/sh- P/C- EPS next 5Y- ROE-141.10% 52W Range3.01 - 9.27 Perf YTD4.68%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-46.85% Beta-
Dividend %- Quick Ratio6.80 Sales past 5Y- Gross Margin- 52W Low63.60% ATR0.34
Employees98 Current Ratio6.80 Sales Q/Q- Oper. Margin- RSI (14)66.66 Volatility6.71% 8.58%
OptionableNo Debt/Eq0.29 EPS Q/Q3.20% Profit Margin- Rel Volume9.19 Prev Close4.25
ShortableYes LT Debt/Eq0.29 EarningsJul 30 BMO Payout- Avg Volume143.47K Price4.92
Recom2.50 SMA2020.53% SMA5017.12% SMA2004.47% Volume284,361 Change15.87%
May-21-20Downgrade Morgan Stanley Overweight → Equal-Weight $8
May-12-20Downgrade Jefferies Buy → Hold $18 → $6
Apr-30-19Initiated Jefferies Buy $18
Jan-29-19Initiated Chardan Capital Markets Neutral $10
Jul-30-20 07:00AM  
Jul-23-20 07:00AM  
Jul-07-20 08:00AM  
Jul-01-20 07:08AM  
Jun-24-20 07:56PM  
Jun-22-20 02:00AM  
Jun-16-20 07:00AM  
May-29-20 12:00PM  
May-28-20 08:00AM  
May-27-20 12:34PM  
May-14-20 02:58PM  
May-11-20 07:00AM  
May-07-20 07:00AM  
May-04-20 09:00AM  
Apr-15-20 07:00AM  
Mar-05-20 07:00AM  
Mar-02-20 07:00AM  
Feb-25-20 12:09PM  
Feb-13-20 07:00AM  
Feb-06-20 08:00AM  
Jan-10-20 07:00AM  
Dec-20-19 06:39PM  
Dec-19-19 08:00AM  
Dec-05-19 07:00AM  
Nov-13-19 08:01AM  
Nov-08-19 07:00AM  
Nov-05-19 07:01AM  
Oct-29-19 08:00AM  
Sep-26-19 04:05PM  
Sep-20-19 07:00AM  
Sep-17-19 07:00AM  
Sep-03-19 08:00AM  
Aug-06-19 10:24PM  
Jul-30-19 08:00AM  
Jul-25-19 08:00AM  
Jul-15-19 08:00AM  
May-30-19 08:00AM  
May-27-19 10:29AM  
May-15-19 08:00AM  
May-08-19 02:23PM  
May-04-19 04:23PM  
May-02-19 07:00AM  
Apr-25-19 07:30AM  
Apr-03-19 08:00AM  
Mar-04-19 07:30AM  
Feb-14-19 07:00AM  
Feb-07-19 08:00AM  
Jan-28-19 06:00AM  
Jan-04-19 06:00AM  
Dec-05-18 08:00AM  
Nov-27-18 08:00AM  
Nov-26-18 08:00AM  
Nov-13-18 08:10AM  
Nov-07-18 08:00AM  
Nov-01-18 08:00AM  
Sep-06-18 08:00AM  
Aug-02-18 08:00AM  
Jun-25-18 08:00AM  
Jun-15-18 06:28PM  
Jun-14-18 08:00AM  
Jun-04-18 08:53AM  
May-31-18 08:00AM  
May-11-18 05:00PM  
May-10-18 07:18AM  
May-08-18 07:29PM  
Evelo Biosciences, Inc., a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815, which are in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of atopic dermatitis, asthma, psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel diseases. The company is also involved in developing EDP150, a monoclonal microbial candidate, which is in Phase 1/2 clinical study for the treatment of colorectal cancer, triple-negative breast cancer, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types. Evelo Biosciences, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Flagship Ventures Fund IV Gene10% OwnerJun 29Buy3.754,666,66617,499,9984,079,032Jul 01 05:24 PM